GIP receptor agonist; gastric inhibitory polypeptide receptor agonist; glucose-dependent insulinotropic polypeptide receptor agonist; GIPR agonist
Jump to navigation
Jump to search
Indications
- treatment of diabetes mellitus type-2 in the dual function hypoglycemic agent tirzepatide
More general terms
More specific terms
Additional terms
- gastric inhibitory polypeptide receptor; GIP receptor; GIP-R; glucose-dependent insulinotropic polypeptide receptor (GIPR)
- gastric inhibitory polypeptide; glucose-dependent insulinotropic polypeptide (GIP)
References
- ↑ Fisman EZ, Tenenbaum A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect. Cardiovasc Diabetol. 2021 Nov 24;20(1):225. PMID: https://www.ncbi.nlm.nih.gov/pubmed/34819089 PMCID: PMC8613929 Free PMC article.
- ↑ Gasbjerg LS, Rosenkilde MM, Meier JJ, Holst JJ, Knop FK. The importance of glucose-dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide. Diabetes Obes Metab. 2023 Nov;25(11):3079-3092. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37551549 Review.